

Date 20 August 2026
Our Ref 11737

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
 - a. Acalabrutinib (Calquence)
 - b. Ibrutinib (Imbruvica)
 - c. Pirtobrutinib (Jaypirca)
 - d. Venetoclax (Venclyxto)
 - e. Zanubrutinib (Brukinsa)
 - f. Rituximab
 - g. Obinutuzumab (Gazyvaro)

Answer:

a.	5<
b.	0
c.	0
d.	32
e.	9
f.	84
g.	14

Question:

2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
 - a. Acalabrutinib (Calquence)
 - b. Ibrutinib (Imbruvica)
 - c. Pirtobrutinib (Jaypirca)
 - d. Venetoclax (Venclyxto)

- e. Zanubrutinib (Brukinsa)
- f. Obinutuzumab (Gazyvaro)
- g. Rituximab

Answer:

a.	5<
b.	5<
c.	0
d.	14
e.	5<
f.	10
g.	5<

Question:

3. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
- a. Acalabrutinib
 - b. Ibrutinib
 - c. Zanubrutinib
 - d. Pirtobrutinib
 - e. Bortezomib
 - f. Lenalidomide

Answer:

a.	5<
b.	0
c.	0
d.	0
e.	0
f.	5<

Question:

4. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as combination or monotherapy in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
- a. Ibrutinib + Venetoclax I+V = 0
 - b. Obinutuzumab + Venetoclax V+O = 10
 - c. Venetoclax + Rituximab V+R = 5 or fewer
 - d. Rituximab + Fludarabine + Cyclophosphamide R-FC = 0
 - e. Rituximab + R-CHOP R-CHOP = 0
 - f. Rituximab + Bendamustine R-Benda = 0

- g. Rituximab + Chlorambucil R-Chlor = 0
- h. Obinutuzumab + Chlorambucil O-Chlor = 0
- i. Acalabrutinib + Venetoclax +/- Obinutuzumab = 5 or fewer

Answer:

a.	0
b.	10
c.	5<
d.	0
e.	0
f.	0
g.	0
h.	0
i.	5<

Question:

5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
- a. Azacitidine
 - b. Cytarabine
 - c. Venetoclax (Venclyxto)

Answer:

a.	26
b.	8
c.	18

Question:

6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of April 2026 and end of June 2026, or latest 3-month period available?
- a. Venetoclax + Azacitidine (with or without posaconazole)
 - b. Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)

Answer:

a.	18
b.	0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive